MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors: an ongoing phase 1/2 study

被引：0

作者：

Ou, S. H. ^{[1
]}

Garcia, V. Moreno ^{[2
]}

Bazo, I. Gil ^{[3
]}

Prenen, H. ^{[4
]}

Moreno, I. ^{[5
]}

Johnson, M. ^{[6
]}

Alvarez, E. Castanon ^{[7
]}

Nagasaka, M. ^{[1
]}

Adeyemi, S. ^{[8
]}

Barasa, B. ^{[9
]}

Bol, K. ^{[10
]}

Doze, P. ^{[10
]}

Engbers, A. ^{[10
]}

Joe, A. K. ^{[10
]}

Stalbovskaya, V. ^{[8
]}

Laus, G. ^{[10
]}

Call, J. ^{[11
]}

机构：

[1] Univ Calif Irvine, Dept Med Div Hematol Oncol, Sch Med, Irvine, CA USA

[2] Start Madrid FJD, Hosp Univ Fdn Jimenez Diaz, Madrid, Spain

[3] Univ Navarra Clin, Dept Med Oncol, Pamplona, Spain

[4] Univ Antwerp Hosp, Oncol, Antwerp, Belgium

[5] HM Sanchinarro Univ Hosp, Start Madrid, CIOCC, Madrid, Spain

[6] Sarah Cannon Res Inst LLC, Lung Canc Res, Nashville, TN USA

[7] Univ Navarra Clin, Dept Med Oncol, Madrid, Spain

[8] Merus, Biometr, Utrecht, Netherlands

[9] Merus, Translat Res, Utrecht, Netherlands

[10] Merus, Clin, Utrecht, Netherlands

[11] START Mt Reg, Med Oncol, Salt Lake City, UT USA

来源：

EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

341

引用

页码：S122 / S122

页数：1

共 50 条

[21] Activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors.
Garralda, Elena
Del Conte, Gianluca
Macchini, Marina
Matos, Ignacio
Klinghammer, Konrad Friedrich
Santa Gadea, Omar Saavedra
Fiedler, Walter M.
Rolling, Christina C.
Kebenko, Maxim
Raspagliesi, Francesco
Larusso, Domenica
Ahrens-Fath, Isabelle
Habel, Beate
Baumeister, Hans
Zurlo, Alfredo
Ochsenreither, Sebastian
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[22] Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors
Ochsenreither, S.
Fiedler, W. M.
Conte, G. D.
Macchini, M.
Matos, I
Habel, B.
Ahrens-Fath, I
Raspagliesi, F.
Lorusso, D.
Keilholz, U.
Rolling, C.
Kebenko, M.
Klinghammer, K. F.
Saavedra, O.
Baumeister, H.
Zurlo, A.
Garralda, E.
ESMO OPEN, 2022, 7 (02)
[23] Phase 1 study of ABBV-400, a novel anti-Met antibody drug conjugate, in advanced solid tumors
Shimizu, Toshio
Powderly, John
Sharma, Manish R.
Guan, Xiaowen
Vasilopoulos, Athanasios
Li, Martha
Li, Rui
Cunningham, Alexis
Reilly, Regina
Morrison-Thiele, Gladys
Freise, Kevin
Aristide, Martha Neagu
Camidge, D. Ross
ANNALS OF ONCOLOGY, 2023, 34 : S1397 - S1397
[24] Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c Study
Xiong, Jianping
Ouyang, Weiwei
Yang, Mengxiang
Gao, Zhenyuan
Zhou, Huan
Lou, Hanmei
Guo, Yabing
Xu, Zhongyuan
Zheng, Ling
Liu, Ying
Wang, Zhongfeng
Sun, Ping
Niyazi, Huerxidan
Wang, Jianhua
Chen, Yan
Zhang, Baihui
Li, Lingyan
Kang, Xiaoyan
Guo, Weijian
ADVANCES IN THERAPY, 2024, 41 (11) : 4153 - 4171
[25] Safety and tolerability results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors.
Ochsenreither, Sebastian
Zurlo, Alfredo
Garralda, Elena
Matos, Ignacio
Klinghammer, Konrad Friedrich
Del Conte, Gianluca
Macchini, Marina
Rolling, Christina C.
Kebenko, Maxim
Gadea, Omar Saavedra Santa
Raspagliesi, Francesco
Larusso, Domenica
Ahrens-Fath, Isabelle
Habel, Beate
Baumeister, Hans
Fiedler, Walter M.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[26] FIH phase I dose escalation and dose expansion study of anti-EGFR ADC MRG003 in patients with advanced solid tumors
Qiu, M.
Guo, Y.
Guo, W.
Nian, W.
Liao, W.
Xu, Z.
Zhang, W.
Zhang, Y.
Wei, X.
Xue, L.
Tang, W.
Wu, Y.
Ren, G.
Wang, L.
Xi, J.
Wang, Y.
Li, M.
Hausheer, F.
Hu, C.
Xu, R.
ANNALS OF ONCOLOGY, 2021, 32 : S804 - S804
[27] Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors
Patricia M. LoRusso
Mrinal Gounder
Shadia I. Jalal
Valérie André
Siva Rama Prasad Kambhampati
Nick Loizos
Jennifer Hall
Timothy R. Holzer
Aejaz Nasir
Jan Cosaert
John Kauh
E. Gabriela Chiorean
Investigational New Drugs, 2017, 35 : 442 - 450
[28] Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors
LoRusso, Patricia M.
Gounder, Mrinal
Jalal, Shadia I.
Andre, Valerie
Kambhampati, Siva Rama Prasad
Loizos, Nick
Hall, Jennifer
Holzer, Timothy R.
Nasir, Aejaz
Cosaert, Jan
Kauh, John
Chiorean, E. Gabriela
INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 442 - 450
[29] A PHASE 1 STUDY OF CABOZANTINIB IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS: ANTI-TUMOR ACTIVITY IN NSCLC AND GIST
Nokihara, H.
Yamamoto, N.
Nakamichi, S.
Wakui, H.
Yamada, Y.
Nguyen, L.
Tamura, T.
ANNALS OF ONCOLOGY, 2013, 24
[30] Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers
Ming-Mo Hou
Ching-Liang Ho
Hsuan-Yu Lin
Yunting Zhu
Xiaodi Zhang
Investigational New Drugs, 2021, 39 : 1315 - 1323

← 1 2 3 4 5 →